Lessons on Urethral Lidocaine in Urodynamics

• Status: Recruiting
• Trial end date: 2021-10-22
• Target enrollment: 0
• Participant gender: Female

Summary

This trial will assess whether use of intraurethral 2% lidocaine jelly meaningfully impacts sensation during filling (i.e., a change of more than 25% of first sensation, first desire to void, strong desire to void, or maximum cystometric capacity) and determine whether the use of intraurethral 2% lidocaine jelly meaningfully impacts pain/discomfort, filling metrics, and voiding metrics.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Texas Southwestern Medical Center
• Treatments: Lidocaine

Criteria

Inclusion Criteria:

• Female patients

• >18 years of age

• Already scheduled (or being scheduled) for UDS to assess urinary incontinence

• Able to speak and read in English

Exclusion Criteria:

• Diagnosis of pelvic pain, interstitial cystitis, or bladder pain syndrome

• Known neurogenic disease impacting voiding/ continence (e.g., Parkinson disease, multiple sclerosis, myasthenia gravis, recent stroke)

• Active UTI

• Pelvic organ prolapse that is unable to be easily reduced

• Pregnancy or breastfeeding

• Allergy or hypersensitivity to lidocaine or local anesthetics